Ratnaveer Precision to list on September 11, expected to gain 40% over issue price

| Leave a Comment | IPO

Ratnaveer Precision Engineering is expected to list on the stock exchanges on September 11 with a gain of at least 40% over its issue price of Rs 98 per share. The grey market premium for the stock is currently at 50%, indicating strong demand from investors.

The company’s IPO was subscribed 93.99 times, with bids for 110.79 crore equity shares against the issue size of 1.17 crore. The IPO included a fresh issue of 17 lakh shares aggregating to Rs 75 crore and an offer for sale (OFS) of 94 lakh shares aggregating to Rs 415 crore.

The company manufactures stainless steel finished sheets, washers, solar roofing hooks, pipes, and tubes. It has a diverse product portfolio and a large headroom for growth in end-user industries such as automotive, solar and wind power plants, and oil and gas.

Analysts advise investors to book profits on the listing day, as the stock is likely to be volatile in the initial days.

Here are some of the reasons why Ratnaveer Precision is expected to list with a gain:

  • Strong demand from investors in the IPO
  • Niche SS cold-rolled products with high margins
  • Investor-friendly IPO pricing
  • Diverse product portfolio with large growth potential
  • Backward integration and industry tailwinds in the Indian stainless-steel sector

However, it is important to note that the stock market is volatile and there is no guarantee that the stock will list at a premium. Investors should do their own research before investing in any stock.


Related News

  • 22 Sep

    Samhi Hotels Stock Lists with 6.75% Premium, Analysts Recommend Booking Profits

    Samhi Hotels stock made a weak debut on the stock exchanges, listing at a premium of just 6.75% over the IPO price. Several analysts have recommended booking profits in the stock, citing its loss-making status and negative net worth.

  • 22 Sep

    Signature Global IPO Subscribed 11.88 Times on Final Day

    The Signature Global IPO was subscribed 11.88 times on the final day of bidding. The company will use the proceeds to repay debt and for land acquisitions and general corporate purposes. The IPO is expected to list on October 4, but this may change due to the new timeline of T+3.

  • 22 Sep

    Sai Silks IPO Oversubscribed 4.4 Times on Final Day of Bidding

    Sai Silks IPO was oversubscribed 4.4 times on the final day of bidding, with qualified institutional buyers and high networth individuals supporting the issue on closing day. The net fresh issue proceeds will be utilized by the company mainly for the setting up of 30 new stores, two warehouses, working capital requirements and repaying debts. The trading in its equity shares will commence with effect from October 4, as per the IPO schedule.

  • 22 Sep

    Pharma company Valiant Laboratories to go public on September 27

    Pharma company Valiant Laboratories is going public on September 27 at a price band of Rs 133-140 per share. The company plans to raise Rs 152.46 crore via the IPO. Proceeds will be used to fund the expenditure for setting up a manufacturing facility for speciality chemicals and for working capital requirements and general corporate purposes. Valiant Laboratories is a Mumbai-based API and bulk drug manufacturing company with a focus on Paracetamol. It is owned by the promoters including Dhanvallabh Ventures LLP, which holds 62.5 percent shareholding. Valiant Organics, the listed entity on the BSE and NSE, is the promoter of Dhanvallabh Ventures LLP with 73.15 percent stake.

  • 21 Sep

    Unihealth Consultancy makes tepid debut on NSE Emerge

    Unihealth Consultancy, a healthcare service provider, made a tepid debut on the NSE Emerge platform on September 21, listing at Rs 135, a 2.2 percent premium over its issue price of Rs 132. The stock was trading at Rs 137.30 at 11.40 am. The company has a number of positives going for it, such as its strong growth potential, its diversified business model, and its focus on the African market. However, investors who are considering investing in Unihealth Consultancy should carefully consider the company's fundamentals, the current market conditions, and their own risk appetite before making a decision.

Leave a Reply

Your email address will not be published. Required fields are marked *